GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » ROA %

Gyre Therapeutics (Gyre Therapeutics) ROA % : -92.34% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Gyre Therapeutics's annualized Net Income for the quarter that ended in Dec. 2023 was $-92.9 Mil. Gyre Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was $100.6 Mil. Therefore, Gyre Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -92.34%.

The historical rank and industry rank for Gyre Therapeutics's ROA % or its related term are showing as below:

GYRE' s ROA % Range Over the Past 10 Years
Min: -92.34   Med: 2.71   Max: 27.62
Current: -92.34

During the past 3 years, Gyre Therapeutics's highest ROA % was 27.62%. The lowest was -92.34%. And the median was 2.71%.

GYRE's ROA % is ranked worse than
81.93% of 1555 companies
in the Biotechnology industry
Industry Median: -35.15 vs GYRE: -92.34

Gyre Therapeutics ROA % Historical Data

The historical data trend for Gyre Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics ROA % Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROA %
27.62 2.71 -92.34

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
ROA % 27.62 2.71 -92.34

Competitive Comparison of Gyre Therapeutics's ROA %

For the Biotechnology subindustry, Gyre Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's ROA % falls into.



Gyre Therapeutics ROA % Calculation

Gyre Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-92.933/( (84.753+116.539)/ 2 )
=-92.933/100.646
=-92.34 %

Gyre Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Dec. 2023 ))/ count )
=-92.933/( (84.753+116.539)/ 2 )
=-92.933/100.646
=-92.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Gyre Therapeutics  (NAS:GYRE) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-92.933/100.646
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-92.933 / 113.45)*(113.45 / 100.646)
=Net Margin %*Asset Turnover
=-81.92 %*1.1272
=-92.34 %

Note: The Net Income data used here is one times the annual (Dec. 2023) net income data. The Revenue data used here is one times the annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Gyre Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines